The DNPH1 Knockout Jurkat Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population in which the DNPH1 gene has been disrupted. This genetically heterogeneous pool of Jurkat cells harbors a variety of targeted edits, yielding a population-level loss-of-function model. The polyclonal format avoids clonal artifacts and enables investigation of DNPH1-dependent processes across a distribution of editing efficiencies.
Jurkat cells are an immortalized human T lymphocyte line originating from an acute T cell leukemia. They are extensively used as a model system for T cell receptor signaling, apoptosis, and leukemogenesis. Their robust proliferation, suspension culture characteristics, and amenability to genetic manipulation make them an ideal host for gene editing, particularly in studies addressing hematopoietic malignancies and immune cell pathology. Jurkat cells retain many features of T-cell biology and provide a physiologically relevant platform for studying oncogenic signaling and drug responses.
DNPH1 (2′-deoxynucleoside 5′-phosphate N-hydrolase 1) functions as a nucleotidase that hydrolyzes deoxyribonucleoside 5′-monophosphates, playing a central role in dNTP pool homeostasis for DNA synthesis and repair. DNPH1 is under transcriptional control of the tumor suppressor TP53 (p53), which induces its expression following genotoxic stress to limit mutagenic nucleotide misincorporation and uphold genomic integrity. Downstream, DNPH1 influences dNTP availability, DNA replication fidelity, and p53-driven apoptotic pathways. Essential pathway mediators include CDKN1A (p21), RRM2B, TYMS, and DUT, linking DNPH1 to cell cycle checkpoints and nucleotide metabolism.
In the Jurkat T-cell acute lymphoblastic leukemia background, DNPH1 disruption offers a powerful tool for dissecting the nexus between nucleotide salvage, p53-dependent stress responses, and leukemia cell viability. Loss of DNPH1 may sensitize cells to nucleoside analog chemotherapeutics and uncover dependencies on compensatory nucleotide pathways. This model permits exploration of how altered dNTP homeostasis contributes to genomic instability and drug susceptibility in a malignant T-cell environment.
The polyclonal DNPH1 knockout cells are well-suited for diverse assays, including dNTP pool measurement via HPLC or LC-MS, cell proliferation and apoptosis assays by flow cytometry, Western blot analysis of p53 and p21, and RT-qPCR quantification of DNPH1 mRNA. Additional applications encompass nucleotide hydrolase activity assays, colony formation under genotoxic stress, DNA damage sensitivity (comet assay, ??H2AX), and drug sensitivity profiling with antimetabolites such as 5-fluorouracil and hydroxyurea. For further information or custom services, please contact Ascent Research.
